Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Cadrenal Therapeutics, Inc. Common Stock
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 3.57M shares outstanding
USCadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation.
The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Leadership
Quang X. Pham
Chairman & Chief Executive Officer
Matthew K. Szot
Co-Founder & Chief Financial Officer
James J. Ferguson FACC
Chief Medical Officer
Jeffrey Cole
Chief Operating Officer
Employees
4
Country
US
Sector
Healthcare
Website
cadrenal.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Pham Quang X | Chairman and CEO | Grant/Award | 200.0K | -- | Oct 9, 2026 |
 WILSON GLYNN | Director | Grant/Award | 75.0K | -- | Oct 9, 2026 |
 Cole Jeffrey Scott | Chief Operating Officer | Grant/Award | 150.0K | -- | Oct 9, 2026 |
 MURPHY JOHN RAYMOND | Director | Grant/Award | 75.0K | -- | Oct 9, 2026 |
 Golden Lee Scott | Director | Grant/Award | 75.0K | -- | Oct 9, 2026 |
| Pham Quang X | Chairman and CEO | Sale | 7.4K | $22.4K | Jun 29, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Quang X. Pham · may incl. warrants· filed Jan 2025 | 421.0K | 11.8% | 13D |
Armistice Capital, LLC · may incl. warrants· filed Nov 2024 | 78.6K | 2.2% | 13G |
Havlickova 648 a.s. · may incl. warrants· filed Feb 2025 | 78.3K | 2.2% | 13G |
John Raymond Murphy · may incl. warrants· filed Jan 2025 | 53.2K | 1.5% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 50.1K | 1.4% | 13F |
HRT FINANCIAL LP | 29.1K | 0.8% | 13F |
COURIER CAPITAL LLC | 19.8K | 0.6% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 19.0K | 0.5% | 13F |
 Szot Matthew K Chief Financial Officer | 9.9K | 0.3% | FORM 4 |
VANGUARD FIDUCIARY TRUST CO | 8.3K | 0.2% | 13F |
Insiders
- Pham Quang XChairman and CEO
- WILSON GLYNNDirector
- Cole Jeffrey ScottChief Operating Officer
- MURPHY JOHN RAYMONDDirector
- Golden Lee ScottDirector
- Szot Matthew KChief Financial Officer
- Ferguson James J. IIIChief Medical Officer
- Zelenkofske StevenDirector
- Lisicki RobertDirector
based on 3.57M shares outstanding
US30d Avg
200.03K
60d Avg
725.87K
90d Avg
482.02K